Jun 25, 2026
Hear from dermatologist Dr. Ron Prussick and cardiologist Dr. Brittany Weber as they discuss the emerging role of GLP-1 receptor agonists in the management of patients with psoriasis. This conversation explores the intersection of psoriatic disease, obesity, and cardiometabolic health, and how these therapies may support improved outcomes.
Learn more about the National Psoriasis
Foundation’s GLP-1 Primer for Dermatologists:
https://www.psoriasis.org/glp-1-primer-for-dermatologists/
Key Takeaways
-
Patients with higher BMI have a lower likelihood of achieving PASI 90 and 100 and a higher risk of developing PsA and other comorbidities.
-
Psoriasis is linked to increased cardiovascular risk, and GLP-1 therapies can address multiple drivers at once, including adiposity, cardiometabolic dysfunction, and inflammatory burden.
-
Patients with psoriasis or psoriatic arthritis who also have metabolic comorbidities such as obesity, insulin resistance, fatty liver disease, or diabetes, as well as related conditions like hidradenitis suppurativa, may be strong candidates for adding GLP-1 agonists alongside standard psoriasis therapies.
This podcast is supported in part by Lilly.